Novartis Gets FDA Approval for Combination Treatment of Advanced Thyroid Cancer

Edward Kim | |

Tafinlar and Mekinist approved to treat BRAF V600E mutation-positive anaplastic thyroid cancer.

Amgen Presents Full Positive Phase 3b Results of Migraine Drug Aimovig

Edward Kim | |

Aimovig cut migraine days in half for 30% of trial patients who had failed up to four previous treatments (Image: PharmaTimes).

Vaccitech Raises £20 Million for Universal Flu Vaccine

Edward Kim | |

Series A led by GV (Alphabet), Sequoia China and Oxford Sciences Innovation.

Advanced Accelerator gets Approval for Gastrointestinal Cancer Drug

Edward Kim | |

First radioactive drug to be approved for gastroenteropancreatic neuroendocrine tumors.

resTORbio IPO on Deck, Less than a Year After Licensing Clinical Programs from Novartis

Edward Kim | |

Rapid path to Nasdaq for company developing treatments for aging-related diseases.

​Pressure BioSciences is Really Cornering Pressure Tech Market

Spotlight Companies | |

The company is stronger than ever heading into 2018.

Lilly Gets FDA Approval for Advanced Breast Cancer Treatment

Edward Kim | |

New targeted treatment option for certain patients with breast cancer who are not responding to existing therapies (Image: National Cancer Institute).

​An ETF for Global Healthcare

MoneyShow | |

Few necessities are as vital as health care.

​Here's The Real Importance Of The Latest Novartis AG (ADR) (NYSE:NVS) News

Mark Collins | |

Here's what just happened with Novartis and why it's so important.

Applied Genetic Technologies (AGTC): Gene Therapy for Opthalmology

Edward Kim | |

AGTC is developing treatments for severe opthalmological diseases using gene therapy.

Humanity. 2.0 - Opening Address at the Vatican

The opening address was delivered by Rev. Philip Larrey, Chairman of. Humanity 2.0, and Matthew. Sanders, CEO & Founder of Humanity 2.0.


Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more